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Abstract
Introduction Experimental studies have demonstrated that
dextran-70 reduces the leukocyte–endothelium interaction, but
clinical evidence is still lacking. Our objective was to justify the
anti-inflammatory effect of dextran-70 following cardiac
operations.
Methods Forty patients undergoing coronary bypass surgery (n
= 32) or aortic valve replacement (n = 8) were enrolled in this
prospective, randomized, double-blind study. Two groups were
formed. In group A (n  = 20), dextran-70 infusion was
administered at a dose of 7.5 ml/kg before the initiation of
cardiopulmonary bypass and at a dose of 12.5 ml/kg after the
cessation of cardiopulmonary bypass. Group B served as a
control with identical amounts of gelatin infusion (n = 20). The
plasma concentration of procalcitonin, C-reactive protein, IL 6,
IL 6r, IL 8, IL 10, soluble endothelial leukocyte adhesion
molecule-1, soluble intercellular adhesion molecule-1, cardiac
troponin-I and various haemodynamic parameters were
measured in the perioperative period. Multivariate methods were
used for statistical analysis.
Results In group A, lower peak (median) plasma levels of
procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8,
p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial
leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033),
intercellular adhesion molecule-1 (806.7 versus 1,375.7, P =
0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found.
There was no significant difference in IL 6, IL-6r and C-reactive
protein values between groups. Higher figures of the cardiac
index (p  = 0.010) along with reduced systemic vascular
resistance (p = 0.005) were noted in group A.
Conclusion Our investigation demonstrated that the use of
dextran-70 reduces the systemic inflammatory response and
cardiac troponin-I release following cardiac operation.
Trial registration number ISRCTN38289094.
Introduction
Cardiac surgery on cardiopulmonary bypass (CPB) results in
a complex immune response characterized by the activation of
all inflammatory pathways and strongly related to increased
postoperative morbidity and mortality. The immune activation
due to systemic inflammatory response syndrome exposes the
patient to postoperative wound healing complications and to
the development of infections [1,2].
Increased levels of the proinflammatory cytokines IL-6 and IL-
8 play a major role in the pathogenesis of ischaemia-reper-
fusion injury [3] and multiple organ dysfunction syndrome [4].
AVR = aortic valve replacement; CABG = coronary artery bypass grafting; CPB = cardiac surgery on cardiopulmonary bypass; cTr-I = cardiac tro-
ponin I; ELISA = enzyme-linked immunosorbent assay; HES = hydroxyethyl starches; ICAM-1 = intercellular adhesion molecule-1; IL = interleukin; NF 
= nuclear factor; PMN = polymorphonuclear leukocyte; sELAM-1 = soluble endothelial leukocyte adhesion molecule-1; SVRI = systemic vascular 
resistance index; TNF = tumour necrosis factor.Critical Care    Vol 11 No 4    Gombocz et al.
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IL-8 is a crucial chemokine, which attracts and activates poly-
morphonuclear leukocytes (PMNs) as well as T lymphocytes,
and controls their migration. Tissue penetration, free radical
production, and granulocyte elastase synthesis and release
are also increased in PMNs [4]. Serum procalcitonin is a sen-
sitive marker for the early detection of systemic inflammatory
response syndrome [5]. Procalcitonin levels above 2 ng/ml are
predictive for postoperative complications after cardiac oper-
ations [6]. Owing to inflammation, soluble adhesion molecules
are shed into the circulation and their concentration correlates
with the magnitude of endothelial activation and injury [1,7].
Several investigations have demonstrated that artificial col-
loids modulate the inflammatory response. Animal experiments
have confirmed that dextran decreases the endothelial adhe-
sion of PMNs in the postischaemic phase independently of the
haemodilution [8]. Among trauma patients, dextran administra-
tion counteracts monocyte dysfunction and the related imbal-
ance between coagulation and fibrinolysis [9]. Hypertonic
saline dextran suppressed myocardial TNF-α, IL-1β and IL-6
secretion after an initial burn injury in an animal study, improv-
ing ventricular performance after subsequent septic challenge
[10]. Experimental and clinical studies have justified the bene-
ficial effects of dextran in the prevention of acute respiratory
distress syndrome following trauma and sepsis [11], radiation
injury [12], pancreatitis [13] and lower limb reperfusion injury
[14].
It has been reported that hydroxyethyl starches (HES) reduce
capillary leakage [15], leading to the concept of 'plugging the
leaks' in various diseases, including sepsis and burns [16]. In
a polymicrobial sepsis model, HES inhibited the inflammatory
cytokine response, neutrophil infiltration and expression of
intercellular adhesion molecule-1 (ICAM-1) mRNA [17]. Other
anti-inflammatory manifestations of low-molecular-weight HES
include impaired neutrophil respiratory burst and reduced neu-
trophil chemotaxis [18]. Administration of HES was associ-
ated with reduced markers of inflammation and endothelial
activation in sepsis [19] and in patients undergoing major
abdominal surgery [20].
Without any evidence of modulating the inflammatory
response, gelatin infusion has been considered pharmacolog-
ically inert [21]. This assumption was confirmed in an experi-
mentally induced acute lung injury model, where the
inflammatory response (TNF-α) and oxidative stress were not
affected by gelatin [22]. A recently published investigation has
also indicated that NF-κB activation, proinflammatory
cytokines levels, ICAM-1 mRNA expression and myeloperoxi-
dase activity were not affected by modified fluid gelatin in a
polymicrobial sepsis model [17] – whereas, like other artificial
colloids, gelatin impairs firm leukocyte adhesion to the
endothelium in vitro [23], and applied in the priming fluid gel-
atin reduces the contact activation of complement cascades
by binding to fragment Ba [24]. Nevertheless an increased
TNF-α release was demonstrated after the incubation of blood
with gelatin in vitro [25], but in vivo investigation has revealed
that gelatin does not alter PMN function [26].
Despite numerous studies having been published concerning
the influence of colloids on inflammation, only few comparative
studies exist. Reducing the endothelial adhesion of PMNs,
dextran was reported to be more potent than HES in leuko-
cyte-related reperfusion injury, and in contrast to HES the anti-
inflammatory effect of dextran developed even in nondilutional
microdose administration [8].
On the basis of experimental data it may be hypothesized that
dextran attenuates the inflammatory response following car-
diac surgery. There are, however, no exact clinical data in the
literature that would support the anti-inflammatory effect of
dextran following cardiac surgery. Our objective was the inves-
tigation of the effects of dextran-70 compared with gelatin as
a control, on the levels of serum procalcitonin, on the inflam-
matory cytokine response, the markers of endothelial damage,
myocardial ischaemia-reperfusion injury and haemodynamics
after CPB. Our hypothesis was that administration of dextran
reduces the level of inflammatory mediators and cardiac tro-
ponin-I (cTr-I) at the most important timepoints.
Materials and methods
With permission from the ethical committee of the hospital, 40
patients undergoing elective first-time CPB – 32 patients
undergoing coronary artery revascularization (coronary artery
bypass grafting (CABG)), eight patients undergoing aortic
valve replacement (AVR) – were involved in this prospective,
randomized, double-blind study after individual consent was
obtained. The setting of the study was single institutional. Two
experienced anaesthesiologists and two experienced sur-
geons were involved in the study. Exclusion criteria were as
follows: 'redo' operation, hepatic disease, renal dysfunction,
immunologic disease, steroid treatment, intake of aspirin or
other cyclooxygenase inhibitor within 7 days prior to surgery,
or known allergy to volume expanders used in the study. None
of the patients received volatile anaesthetics, steroids or apro-
tinin and haemofiltration was not used either. No shed medias-
tinal blood was retransfused during the postoperative period.
Two groups were formed following computerized randomiza-
tion. Twenty patients (CABG, 17 patients; AVR, three
patients) were given dextran-70 (6%; average molecular
weight 70,000 Da) infusion (Macrodex; Pharmalink, Inc., Upp-
lands Väsby, Sweden) (group A), while in the control group 20
patients (CABG, 15 patients; AVR, five patients) were given
oxypolygelatin (5.5%; average molecular weight 30,000 Da)
infusion (Gelifundol; Biotest Pharma, Inc., Dreieich, Germany)
(group B). Following the induction of anaesthesia, artificial col-
loid was administered using infusion pumps (Model 591;
IVAC, Inc., San Diego, CA, USA). After the application of hap-
ten inhibition by 20 ml dextran-1 (Promit; Fresenius Kabi, Inc.,Available online http://ccforum.com/content/11/4/R87
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Norge AS, Norway), dextran-70 infusion was used at the dose
of 7.5 ml/kg for 30 minutes before CPB, and at a dose of 12.5
ml/kg for 14 hours following the cessation of CPB. Gelatin
was infused by the same body-weight-based volume as dex-
tran. The indication of the colloid administration was volume
substitution. Depending on the actual haemodynamic and
volume status, crystalloid infusion was administered together
with a fixed dose of colloid.
Anaesthesia was carried out by a standardized total intrave-
nous method. Premedication was achieved with midazolam.
For the induction of anaesthesia, midazolam, propofol in a tar-
get controlled infusion perfusion device using Diprifusor™
(Alaris Medical Systems, Hampshire, UK), alfentanil and pipe-
curonium were used, while propofol (target controlled infu-
sion) and alfentanil were given to maintain anaesthesia.
Anticoagulation was maintained with heparin (initial value 300
IU/kg) to keep the activated clotting time longer than 400 sec-
onds. Protamine was administered in a 1:1 ratio based on the
initial heparin bolus (necessary to achieve the target activated
clotting time). Cardiopulmonary bypass was carried out in nor-
mothermia, with the use of a roller pump (Cobe Cardiovascu-
lar, Inc., Arvada, Colorado USA), with pulsatile flow rate of 2.4
l/min/m2  and a membrane oxygenator (Affinity™ NT 541;
Medtronic, Inc., Minneapolis, MN, USA). Antegrade, cold,
crystalloid cardioplegia (modified Bretschneider solution)
injected into the aortic root was used for myocardial protec-
tion. The Pulsion PiCCO™ (Pulsion Medical Systems, Inc.,
München, Germany) device was used for haemodynamic
monitoring.
Packed red blood cell administration was applied when the
haemoglobin level was less then 90 g/l, or during CPB when
haemoglobin was below 70 g/l. Postoperative complications
were defined as follows: cardiovascular complication (low car-
diac output with cardiac index <2.2 l/min/m2 after volume infu-
sion, requiring the use of positive inotrop agents and/or
intraaortic balloon pump); perioperative myocardial infarction
with typical electrocardiogram changes and creatine kinase
MB >75 U/ml (three times the upper limit of the reference
range); acute lung injury (prolonged ventilation, PaO2/FiO2
ratio <200); acute renal failure (serum creatinine >230 μmol/
l); neurologic complications (stroke, ischaemic insults); gas-
trointestinal complications (ischaemia, bleeding); and
infections.
Arterial blood samples were taken from the indwelling femoral
artery cannula at the following time intervals: t1, before anaes-
thesia; t2, 10 minutes after CPB; t3, 2 hours after CPB; t4, 4
hours after CPB; t5, 24 hours after CPB; and t6, 44 hours
after CPB. At the same timepoints, the following haemody-
namic parameters were registered: heart rate, arterial blood
pressure, cardiac index, stroke volume index, stroke volume
variation, systemic vascular resistance index (SVRI), intratho-
racic blood volume index, and extravascular lung water index.
The haematocrit (packed cell volume), haemoglobin and blood
cell count were measured at all time intervals. Determination of
the plasma concentration of inflammatory mediators – inter-
leukins (IL-6, IL-6r, IL-8, IL-10) and soluble adhesion mole-
cules (soluble endothelial leukocyte adhesion molecule-1
(sELAM-1), soluble ICAM-1) – was carried out by ELISA (DIA-
CLONE Research™, Besançon, France) complying with the
technologic regulations of the manufacturer. Blood samples
were centrifuged with a cooled centrifuge at 1,000 × g for 15
minutes. Centrifuged plasma was stored at -86°C.
Three plasma samples were analysed for cytokine and soluble
adhesion molecule levels with the sampling timepoints based
on the kinetics of the single mediators according to the data in
the literature. In each case the first measurement point was the
preoperative control value, the second was the expected max-
imal value of the given mediator after cardiac surgery, while the
third measurement point was the value corresponding to the
dropoff phase [1,7]. The t1, t3 and t4 samples were analysed
for IL-6 and IL-6r, while for IL-8 and IL-10 determinations the
t1, t2, and t3 samples were used. Monitoring of the adhesion
molecules was done as follows: sELAM-1 at the t1, t4 and t5
timepoints, and soluble ICAM-1 as the t1, t5 and t6 samples.
The average of the duplicated ELISA test results was cor-
rected using the following equation: corrected concentration
= noncorrected concentration × actual plasma fraction/
plasma fraction of the t1 sample. Procalcitonin was measured
using an immunoluminometric assay (reference range 0–0.5
ng/ml; LUMItest™; BRAHMS GmbH, Berlin, Germany). For
the measurement of serum C-reactive protein the immune tur-
bidimetric method was used (reference range 0–10 mg/l;
DIALAB™, Vienna, Austria). cTr-I was measured by a two-site
immunoluminometric assay (reference range 0–0.03 ng/ml;
LIAISON™ Troponin I; DiaSorin S.p.A, Saluggia, Italy). For pro-
calcitonin measurements we used the t1 and t5 blood sam-
ples, while for C-reactive protein the t1, t5 and t6 samples
were used, and for cTr-I the t1, t4, t5 and t6 samplings were
used.
Statistical analysis
Statistical analysis was performed by SPSS for Windows 9.0
software (SPSS Inc., Chicago, Illinois, USA). After obtaining
the results for 22 patients a midterm analysis was performed
to calculate the necessary total sample size – Altman's nomo-
gram [27] was used after calculating the standardized differ-
ence of the inflammatory mediators, setting the statistical
power at 80% and choosing a 5% significance level. In the
case of IL-8, IL-10, ICAM-1 and procalcitonin, the standard-
ized difference and the necessary sample size were (0.924)
36, (0.886) 39, (1.326) 19 and (1.041) 29, respectively.
According to the midterm analysis the sample size was deter-
mined to be 40 patients.
For the comparison of the basic data, the chi-squared test and
Student's t test were used. We checked the parameters forCritical Care    Vol 11 No 4    Gombocz et al.
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normal distribution by the Kolmogorov–Smirnov test. If the
result proved significant, the nonparametric test was used
consecutively. Among inflammatory markers and cTr-I, nonpar-
ametric methods were used (Kruskal–Wallis test, Friedman
test); and for haemodynamic parameters the general linear
model repeated-measurement analysis (analysis of variance)
with Bonferroni adjustment for multiple comparison was used
for the analysis of the intraindividual and interindividual differ-
ences. Any difference was regarded statistically significant if p
< 0.05. The results are displayed in the form of the mean ±
standard deviation, as the median (range), or as a box-plot
where the median, 25–75% and 2.5–97.5% percentile
ranges are depicted.
Results
Past medical and perioperative data of the two groups are pre-
sented in Table 1. No operative mortality, low cardiac output,
lung injury, renal failure, neurological complications, gastroin-
testinal complications, surgical intraoperative problems or
wound healing problems occurred among the patients
involved in the study. Myocardial infarction had developed in
three cases, one case in group A and two cases in group B.
Positive inotrope drug was not applied after the operation, and
no differences were found in the frequency of vasodilator ther-
apy (p = 0.584) or β-blocker therapy (p = 0.333) between the
groups. The total postoperative mediastinal and pleural drain-
age proved to be higher in group A. Nevertheless, the amount
of the transfused red blood cell units did not differ between the
two groups. There was also no significant difference between
the preoperative and the 44-hour postoperative haematocrit
values, which indicates that the red blood cell loss was
approximately the same in both groups.
The peak level of procalcitonin was lower in group A (Figure
1.). The procalcitonin level was below 2 ng/ml for all of the
patients in group A, but it increased in 40% of the patients in
group B with a peak level higher than 2 ng/ml (P = 0.001). IL-
8 level elevation was moderate in group A in contrast to the
increase experienced in the control group, which is a well-
known characteristic of CPB. The between-group difference
in IL-8 was significant after CPB (Figure 2). The same kinetics
were found for IL-10 (Table 2). The preoperative concentration
Table 1
Anamnestic and perioperative data
Group A Group B p valuea
Age (years) 61.1 ± 6.5 62.5 ± 7.6 0.535
Gender (male/female) 13/7 14/6 0.736
Body mass index (kg/m2) 28.7 ± 3.9 28.9 ± 3.8 0.821
Hypertension (%) 47.2 52.8 0.292
Diabetes mellitus (type I/type II/impaired glucose tolerance) (%) 2/4/1 2/3/1 0.733
Preoperative ejection fraction (%) 55.6 ± 12.6 56.1 ± 9.7 0.906
EuroScore (log) (%) 2.5 ± 1.2 2.9 ± 1.4 0.405
Amount of plasma substitute (ml) 1626 ± 212 1606 ± 205 0.725
Amount of crystalloids (ml) 4172 ± 660 4107 ± 665 0.765
Number of anastomoses (coronary artery bypass graft) 3.5 ± 1.0 3.5 ± 0.9 0.991
Aortic Xclamp (min) 53 ± 13.8 59 ± 18.1 0.403
Cardiac surgery on cardiopulmonary bypass duration (min) 83 ± 23.7 90 ± 29.3 0.401
Operation time (min) 249 ± 64.5 258 ± 61.7 0.634
Minimum rectal temperature (°C) 34.8 ± 0.6 35.0 ± 0.5 0.274
Preoperative packed cell volume 0.40 ± 0.034 0.39 ± 0.040 0.723
Postoperative 44 hours packed cell volume 0.30 ± 0.035 0.30 ± 0.035 0.623
Postoperative drainage (44 hours, ml) 818 ± 286 588 ± 179 0.005
Red blood cell transfusion (U) 1.8 ± 1.3 1.6 ± 1.2 0.548
Extubation time (hours) 9.2 ± 4.1 9.3 ± 4.6 0.894
Intensive care unit stay (hours) 54 ± 23 47 ± 6 0.209
Hospital stay (days) 9.9 ± 2.4 8.9 ± 1.3 0.114
Data presented as the mean ± standard deviation. aChi-squared test or Student's t test.Available online http://ccforum.com/content/11/4/R87
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of sELAM-1 was higher in group A, and did not increase any
further, in contrast to the control group that started at a low
preoperative value and subsequently rose significantly (Table
2). The level of soluble ICAM-1 did not show any increase in
group A. On the contrary, there was a significant and charac-
teristic increase in the control group. The between-group dif-
ferences for soluble ICAM-1 were significant after CPB
(Figure 3). No significant difference was found in C-reactive
protein, IL-6 or IL6r between the groups. The cTr-I levels were
lower in group A, especially at the t5 timepoint (Table 2).
No difference was found between CABG and AVR patients in
the inflammatory markers or cTr-I, except for ICAM-1 in group
B, which was higher among AVR patients before operation (p
= 0.047) and at the 24-hour timepoint (p = 0.023).
Patients with postoperative atrial fibrillation or pacemaker
rhythm in the VVI mode (group A, five patients; group B, four
patients) were excluded from the analysis of haemodynamic
data. The cardiac index and stroke volume index were higher
while the SVRI figures were lower in group A, with an
Table 2
Results of the inflammatory mediators and cardiac troponin I
t1 t2 t3 t4 t5 t6 p
C-reactive protein (mg/l)
Group A 3.7 (1.0–22.6) 79.9 (50.0–131.7) 112.0 (61.1–177.6) <0.001†
Group B 2.6 (0.6–10.5) 87.6 (52.4–143.0) 131.0 (71.0–228.0) <0.001†
p = 0.068* p = 0.092* p = 0.168*
IL-6 (pg/ml)
Group A 1.6 (0.4–21.8) 95.0
(13.6–405.1)
46.3
(16.1–149.5)
<0.001†
Group B 2.0 (0.4–60.6) 130.5
(21.7–353.8)
49.2
(14.8–214.5)
<0.001†
p = 0.107* p = 0.829* p = 0.482*
IL-6r (ng/ml)
Group A 43.6 (1.7–125.0) 47.4
(0.7–109.5)
56.2
(25.2–226.3)
0.949†
Group B 40.7 (15.6–94.6) 42.4
(22.2–100.5)
50.2
(13.2–104.9)
0.861†
p = 0.607* p = 0.914* p = 0.304*
IL-10 (pg/ml)
Group A 1.9 (0.2–24.0) 47.2 (2.3–476.6) 7.2
(1.3–90.9)
<0.001†
Group B 2.6 (0.8–9.7) 209.7 (16.3–814.3) 56.1
(3.6–225.1)
<0.001†
p = 0.136* p = 0.001* p = 0.001*
Soluble endothelial leukocyte adhesion molecule-1 (ng/ml)
Group A 88.6 (49.8–194.5) 88.5
(14.4–189.6)
72.7 (8.9–163.1) 0.058†
Group B 49.0 (18.3–144.1) 130.7
(33.0–360.7)
72.6 (16.7–224.7) <0.001†
p < 0.001* p = 0.033* p = 0.957*
Cardiac troponin-I (ng/ml)
Group A 0.02 (0.01–0.022) 0.22 (0.07–0.85) 0.13 (0.03–0.75) <0.001†
Group B 0.01 (0.01–0.016) 0.66 (0.10–1.28) 0.19 (0.03–0.80) <0.001†
p = 0.520* p = 0.018* p = 0.097*
Data presented as the median (range). t1, before anaesthesia; t2, 10 minutes after cardiac surgery on cardiopulmonary bypass (CPB); t3, 2 hours 
after CPB; t4, 4 hours after CPB; t5, 24 hours after CPB; t6, 44 hours after CPB. †Intraindividual differences (Friedman test), *between-group 
differences (Kruskal–Wallis test).Critical Care    Vol 11 No 4    Gombocz et al.
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observed statistical power of 83%. The intrathoracic blood
volume index, stroke volume variation, heart rate, arterial blood
pressure (systolic) (p = 0.787), arterial blood pressure (diasto-
lic) (p = 0.771) and extravascular lung water index (p = 0.326)
did not differ between the two groups (Table 3).
Discussion
For the first time according to the literature, we have shown in
the present investigation that dextran-70 reduces the inflam-
matory cytokine response, reduces the peak levels of serum
procalcitonin and reduces the peak levels of the markers of
endothelial activation or damage during the inflammatory acti-
vation following CPB. Earlier investigation had indicated that
dextran-70 reduces complement-3 activation product levels
during cardiopulmonary bypass [28], but subsequently it was
revealed that fresh frozen plasma, which was applied in the
control group in large volume, contains a high level of comple-
ment-3 [29].
The exact mechanism of the anti-inflammatory effect of dextran
is still unclear. Intravital studies on haemodilution in controlled
ischaemia have shown that dextran reduces leukocyte adhe-
sion onto the endothelium. The inhibition of leukocyte–
endothelium interaction already occurs in the pharmacological
microdose of dextran, independently of the haemodilution
effect [8]. On the basis of recently published experimental
data, dextran inhibits neutrophil adhesion by a neutrophil-
dependent mechanism, regulating integrin function rather than
interfering with endothelial cell activation [23]. In the same
Figure 1
Procalcitonin plasma levels before operation and 24 hours after cardi- opulmonary bypass Procalcitonin plasma levels before operation and 24 hours after cardi-
opulmonary bypass. Procalcitonin (PCT) plasma levels in the treated 
and control groups, before operation (t1) and 24 hours after cardiopul-
monary bypass (t5). Significant elevation was found in both groups 
(*Friedman tests). After the operation, procalcitonin was lower in group 
A. The between-group difference was significant (+ Kruskal–Wallis 
test).
Figure 2
IL-8 plasma levels before operation and after cardiopulmonary bypass IL-8 plasma levels before operation and after cardiopulmonary bypass. 
IL-8 plasma levels in the treated and control groups, before operation 
(t1) and 10 minutes (t2) and 2 hours (t3) after cardiopulmonary bypass. 
Significant elevation was found in both groups (*Friedman tests). At t2 
and t3 the IL-8 plasma levels were lower in group A. The between-
group differences were significant (+Kruskal–Wallis test).
Figure 3
Soluble intercellular adhesion molecule 1 plasma levels before opera- tion and after cardiopulmonary bypass Soluble intercellular adhesion molecule 1 plasma levels before opera-
tion and after cardiopulmonary bypass. Soluble intercellular adhesion 
molecule 1 (ICAM-1) plasma levels in the treated and control groups, 
before operation (t1) and 24 hours (t5) and 44 hours (t6) after cardiop-
ulmonary bypass. No elevation was found in group A, but the elevation 
was significant in group B (*Friedman tests). The between-group differ-
ences were significant after cardiac surgery on cardiopulmonary 
bypass (+Kruskal–Wallis test).Available online http://ccforum.com/content/11/4/R87
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experimental setting, gelatin represented a similar effect on
neutrophil adhesion to that of dextran; therefore, it can be sup-
posed that other mechanisms should also be of importance.
The termination of a neutrophil-mediated inflammatory
response is effected through apoptosis of the neutrophils.
When PMNs were exposed to dextran in whole blood sam-
ples, significant apoptosis was demonstrated. By these
effects, human PMN survival was found to decrease [30].
Inflammatory mediators also modulate PMN survival. IL-8 plays
a major role in the markedly reduced rate of programmed cell
death of neutrophils after CPB [31]. In the present investiga-
tion we have demonstrated the attenuation of IL-8 release by
dextran-70. The free radical scavenger effect of dextran is also
well known [8]. This action may contribute to the reduction of
endothelial activation and injury after CPB, as clearly demon-
strated in our investigation.
From the good predictive value of procalcitonin [6] and its
blunted kinetics in the dextran-treated group in our study, one
can suppose that dextran-70 may influence the patients' out-
come after CPB. Further large-scale studies are required to
confirm this assumption.
In our investigation a similarly blunted peak level of IL-8 was
found after dextran-70 administration as that reported earlier
by Wan and colleagues on coronary patients operated on
without CPB [32]. IL-8 plays an important role in the formation
of the myocardial and pulmonary ischaemia-reperfusion injury
developing after the use of CPB [3,7,33]. Its serum concentra-
tion correlates with postoperative cTr-I values [33]. The peak
plasma IL-8 level also correlates with the magnitude of the
proximal tubular injury following CABG surgery [34]. On the
basis of our results, a lower IL-10 peak concentration occurred
proportionally with the IL-8 peak level when dextran infusion
was used, which indicates that no imbalance developed
between proinflammatory and anti-inflammatory responses.
High doses of aprotinin or a heparin-coated CPB tubing set
also reduce IL-10 production following CPB [33,35]. Steroids
increase the concentration of IL-10 with the consequences of
immune suppression [35,36].
We found no significant action of dextran-70 on the levels of
C-reactive protein, IL-6 and IL-6r, but the peak concentration
of IL-6 and C-reactive protein was lower and that of IL-6r was
higher in the group administered dextran. Previous investiga-
Table 3
Results of the haemodynamic data
t1 t2 t3 t4 t5 t6 p valuea
Heart rate (l/min) 0.925
Group A 60 ± 12 76 ± 14 78 ± 13 84 ± 18 84 ± 7 92 ± 10
Group B 59 ± 8 72 ± 9 78 ± 12 81 ± 12 87 ± 12 97 ± 12
Stroke volume index (ml/m2) 0.026
Group A 38.5 ± 6.5 33.5 ± 9.1 31.9 ± 8.2 32.8 ± 9.0 36.9 ± 13.8 36.1 ± 7.4
Group B 36.4 ± 5.7 30.2 ± 5.8 27.6 ± 8.0 27.6 ± 7.5 31.3 ± 10.0 30.1 ± 5.0
Cardiac index (l/min/m2) 0.010
Group A 2.3 ± 0.45 2.4 ± 0.39 2.4 ± 0.63 2.7 ± 0.63 3.0 ± 0.98 3.4 ± 0.94
Group B 2.2 ± 0.36 2.2 ± 0.31 2.0 ± 0.41 2.2 ± 0.44 2.6 ± 0.38 2.9 ± 0.49
Stroke volume variation (%) 0.873
Group A 1.5 ± 0.8 2.3 ± 3.3 3.4 ± 5.3 2.2 ± 1.8 4.5 ± 11.5 2.0 ± 0.7
Group B 2.6 ± 3.9 3.1 ± 2.9 4.9 ± 8.5 2.8 ± 3.1 2.5 ± 1.5 2.5 ± 1.0
Intrathoracic blood volume index (ml/m2) 0.387
Group A 861 ± 132 829 ± 129 875 ± 120 882 ± 122 923 ± 137 975 ± 136
Group B 845 ± 153 811 ± 151 831 ± 192 831 ± 169 871 ± 128 919 ± 214
Systemic vascular resistance index (dyn s/cm5 m2) 0.005
Group A 2,663 ± 414 2,031 ± 492 2,701 ± 604† 2,418 ± 534 2,076 ± 514 2,052 ± 430
Group B 2,732 ± 424 2,279 ± 428 3,499 ± 964 2,902 ± 659 2,470 ± 505 2,227 ± 507
Data presented as the mean ± standard deviation. t1, before anaesthesia; t2, 10 minutes after cardiac surgery on cardiopulmonary bypass (CPB); 
t3, 2 hours after CPB; t4, 4 hours after CPB; t5, 24 hours after CPB; t6, 44 hours after CPB. aBetween-group differences, general linear model 
repeated measurement analysis (analysis of variance). †p < 0.05 (with Bonferroni adjustment for multiple comparison).Critical Care    Vol 11 No 4    Gombocz et al.
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tions proved that IL-6 [33,37] and C-reactive protein [2] levels
did not differ in CABG and off-pump coronary artery bypass
surgery, but reduced IL-6 levels occurred after minimally inva-
sive direct coronary artery bypass surgery, which suggests
that operative trauma itself rather than CPB or ischaemia-
reperfusion injury initiates the release of these factors [2].
These results suggest that dextran can reduce the inflamma-
tion resulted from either the use of CPB or ischaemia-reper-
fusion injury rather than from operative trauma.
There is an increasing body of evidence that the damaging
effect of ischaemia-reperfusion in the heart is related to inflam-
matory processes [3] and that attenuation of the inflammatory
response improves myocardial outcome following cardiac sur-
gery [36]. The pattern of cardiac cTr-I release is similar after
CABG and after valve surgery, but off-pump coronary artery
bypass surgery results in less elevation than CABG using
CPB [38]. Troponin-I release was reduced in the patient group
where dextran-70 was applied, which may indicate that dex-
tran-70 decreases the ischaemia-reperfusion injury after car-
diac operation. The difference in cTr-I was rather small
between the two groups, and therefore its clinical relevance
must be confirmed in a large-scale study.
In our investigation dextran infusion has increased the stroke
volume index independently of the preload by the reduction of
the systemic vascular resistance index. Although the intratho-
racic blood volume index and stroke volume variation did not
differ between the groups it cannot be excluded that the
observed differences in haemodynamics are partly due to the
different volume effects of dextran and gelatin – whereas on
the basis of our sELAM-1 and soluble ICAM-1 results, dextran
infusion reduces the degree of the endothelial damage and
activation. Particularly high preoperative sELAM-1 plasma
concentration figures were found in the dextran group in con-
trast to the control group, indicating higher preoperative
endothelial dysfunction among these patients. The levels of
sELAM-1 and ICAM-1 significantly increased in the control
group, but did not change in those patients who received dex-
tran. This effect on the activation and damage of the endothe-
lium may explain dextran's favourable influence on the
vasomotor regulatory disturbance. Cardiopulmonary bypass
alters vasomotor regulation, reducing the endothelium-
dependent relaxation [39]. The nitric oxide production is signif-
icantly reduced up to 6 hours after CPB [40], which coincides
with the time interval where the main difference in the SVRI
was found in our study.
For the statistical analysis, six series of observations were rep-
resented over time to show the haemodynamic status at every
examined timepoint of the inflammatory mediators. Using
Bonferroni correction for multiple comparison, these many
timepoints have resulted in a very high correction factor,
increasing the possible statistical error, which may mask real
differences. Although the observed statistical power was high,
particularly in case of the SVRI, the clinical relevance of these
finding must be justified in a study investigating a larger
population.
The administration of HES 130/0.4 has also been investigated
on the inflammatory response in other patient populations (for
example, in patients undergoing major abdominal surgery).
The IL-6, IL-8 and soluble ICAM-1 release was found to be
lower in the HES-treated group, but the concentration of
sELAM-1 was similar in the HES-treated and in the lactated
Ringer's solution-treated groups [20]. Although HES does
possesses anti-inflammatory properties [17,18], as the
authors concluded these results were probably due to differ-
ences in microcirculation, because crystalloid-based volume
therapy may worsen the microcirculatory blood flow and tissue
oxygenation despite sufficient haemodynamic conditions [41].
The microhaemodynamic status was not measured in our
investigation, but previously gelatin had been shown to
increase cerebral blood flow velocity and to improve
cutaneous microcirculation, more expressively than HES, dur-
ing haemodilution (to a haematocrit level of 30.0%). That
effect on microcirculation was related inversely to haematocrit,
which means that after autologue blood retransfusion the
parameters of cutaneous microcirculation have worsened
[42]. Similarly to dextran, in our investigation HES was shown
to diminish the endothelial activation or damage in critically ill
patients. The soluble ICAM-1 and sELAM-1 levels did not
increase following HES administration compared with the
increase of these molecular levels in the control group treated
with human albumin (20%).
On the basis of comparative animal experiments investigating
the effects of colloids on leukocyte-endothelial interaction we
have investigated the presumably most effective colloid,
dextran-70, during CPB and we have proved its anti-inflamma-
tory effect. Having said that, questions still remain of whether
dextran has any advantage over other colloids in the anti-
inflammatory properties in clinical situations, and whether it
results in real clinical benefit on patient outcome. Further clin-
ical studies are required to compare the anti-inflammatory
effect of dextran with that of HES, and large-scale clinical stud-
ies must justify that the reduction of inflammation by dextran
can be translated into clinical benefit. Another question to be
raised is whether dextran administrated in a microdose is, or is
not, able to reduce the inflammation in clinical situations of
systemic inflammatory response syndrome, as in experimental
studies [8], because microdose administration eliminates the
antihaemostatic effects.
Blood loss was higher in the dextran group than the control
group, which can be explained by the higher antihaemostatic
potential. This difference, however, is surprisingly not clinically
significant, since the number of red blood cell transfusions and
haematocrit levels did not differ.Available online http://ccforum.com/content/11/4/R87
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The limitation of this study is that gelatin, or any other colloid,
administrated in the control group cannot be considered neu-
tral concerning the inflammatory response. An infusion pos-
sessing anti-inflammatory effects is more acceptable for the
control group than an infusion with proinflammatory features.
Although gelatin administration did not influence neutrophil
infiltration, NF-κB activation, proinflammatory cytokines levels,
ICAM-1 mRNA expression and myeloperoxidase activity in a
septic model [17], a moderate favourable effect on inflamma-
tion was indicated, reducing the Ba fragment of the comple-
ment cascade [24] and impairing the firm leukocyte adhesion
in an in vitro model [23]. Certain albumin batches possess
well-documented proinflammatory actions (for example, acti-
vating E-selectin, ICAM-1, vascular cell adhesion molecule 1),
which seriously question the relevance of human albumin as a
valid control for studies concerning inflammation [43]. Also,
the use of lactated Ringer infusion is associated with signifi-
cant neutrophil activation [44] and early expression of
endothelial E-selectin and P-selectin [45]. Another limitation of
this study is the single institutional setting. There were no dif-
ferences in morbidity, mortality or length of intensive care unit
stay between the groups but the low number of patients in our
study does not allow one to conclude on the clinical outcome
parameters.
Conclusion
To the best of our knowledge our investigation is the first to
show that dextran-70 reduces the inflammatory cytokine
response, the liberation of some soluble adhesion molecules
and the peak level of procalcitonin following cardiac opera-
tions. These results suggest that dextran can reduce the
inflammation resulting from either the use of CPB or ischae-
mia-reperfusion injury rather than from operative trauma.
Further large-scale clinical studies are required to demon-
strate this effect on patient outcome after cardiac surgery.
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